Open the map

RegeneronREGN

Biotech & innovation · NASDAQ · USA

$739.57
Down 0.3% todayClose

Down 3.9% this year but +16.9% since June 26, ahead of the life science sector at +10.7%. Regeneron buys from 4 mapped companies.

Market cap
$76.4B
This year
−3.9%
1 year
+27.2%
P/E
17.7
P/S
4.9
P/B
2.4

Price vs the life science sector

since Jun 26REGNLife science sector, equal weight
Regeneron (REGN) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. REGN: +16.9% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%+30%Jun 26AugSepOct 8REGN +16.9%Sector +10.7% Regeneron (REGN) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. REGN: +16.9% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+10%+20%+30%Jun 26AugSepOct 8REGN+16.9%Sector+10.7%

Supply chain

4 suppliers
SUPPLIERS →→ CUSTOMERSDanaher (DHR)DHRDanaher−0.5%Illumina (ILMN)ILMNIllumina−1.2%West Pharmaceutical Services (WST)WSTWest Pharmaceutical…−0.9%Charles River Laboratories (CRL)CRLCharles River Labor…−0.8%None mappedREGNRegeneron

Suppliers 4

Open the full chain →

About Regeneron

Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.

Theme exposure

BiotechImmunologyOncology

Products

  • Ophthalmology (Eylea)
  • Immunology (Dupixent, with Sanofi)
  • Oncology

Competitors

Risks

  • Competition on Eylea
  • Dependence on partner products

Same segment: Biotech & innovation

Innovation-driven biotech companies focused on novel treatment modalities. Segment 3 of 8 in the Medicine, pharma & life science value chain.

AmgenAMGN−1.4%Gilead SciencesGILD+0.2%Vertex PharmaceuticalsVRTX−0.5%ModernaMRNA+0.3%BiogenBIIB−1.7%Alnylam PharmaceuticalsALNY+0.1%United TherapeuticsUTHR−2.2%IncyteINCY−0.6%

Compare REGN

Side by side with the largest companies in the same segment.

REGN vs AMGNREGN vs GILDREGN vs VRTXREGN vs MRNAREGN vs BIIBREGN vs ALNY

See where Regeneron sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →